In populations with added comorbidities, results are lower: TRIUMPH-2 (obesity + diabetes) showed 20.8%, TRIUMPH-3 (obesity + cardiovascular disease) showed 22.6%, and TRANSCEND-T2D-1 (diabetes-specific, 40 weeks) showed 16.8% all consistent with patterns seen across the GLP-1 drug class, where comorbidities reduce achievable weight loss
Switching from Ozempic to Wegovy is indeed possible, but it should be done under the guidance and supervision of a healthcare provider
If it is dispensed through a clinic or health care provider, it is more likely to be safe and effective. As for brand-name Wegovy, the shortage has been resolved, so this brand-name weight loss medication (made by Novo Nordisk) should now be available at a pharmacy near you
Can patients finance weight loss procedures with a MERP or HRA
Frequently Asked Questions Can I use semaglutide that has been left out overnight